(MedPage Today) — WASHINGTON — A large percentage of people with metabolic dysfunction-associated steatotic liver disease (MASLD) had their liver fat content normalize with an investigational dual agonist of the GLP-1 and glucagon receptors…
Source link : https://www.medpagetoday.com/meetingcoverage/aasld/118499
Author :
Publish date : 2025-11-13 15:53:00
Copyright for syndicated content belongs to the linked Source.
